These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 16004664

  • 1. Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease.
    Dean BB, Dylan M, Gano A, Knight K, Ofman JJ, Levine BS.
    Curr Med Res Opin; 2005 Jul; 21(7):981-7. PubMed ID: 16004664
    [Abstract] [Full Text] [Related]

  • 2. r.hu-erythropoietin (EPO) treatment of pre-ESRD patients slows the rate of progression of renal decline.
    Tapolyai M, Kadomatsu S, Perera-Chong M.
    BMC Nephrol; 2003 Jun 17; 4():3. PubMed ID: 12809563
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the Modification of Diet in Renal Disease and Cockcroft-Gault equations for dosing antimicrobials.
    Hermsen ED, Maiefski M, Florescu MC, Qiu F, Rupp ME.
    Pharmacotherapy; 2009 Jun 17; 29(6):649-55. PubMed ID: 19476418
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin converting enzyme inhibitors impair recombinant human erythropoietin induced erythropoiesis in patients with chronic renal failure.
    Qureshi IZ, Abid K, Ambreen F, Qureshi AL.
    Saudi Med J; 2007 Feb 17; 28(2):193-6. PubMed ID: 17268695
    [Abstract] [Full Text] [Related]

  • 5. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.
    Onuigbo MA, Onuigbo NT.
    QJM; 2008 Jul 17; 101(7):519-27. PubMed ID: 18375475
    [Abstract] [Full Text] [Related]

  • 6. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance.
    Saudan P, Halabi G, Perneger T, Wasserfallen JB, Wauters JP, Martin PY, Western Switzerland Dialysis Group.
    J Nephrol; 2006 Jul 17; 19(1):91-6. PubMed ID: 16523432
    [Abstract] [Full Text] [Related]

  • 7. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 8. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
    Siu YP, Leung KT, Tong MK, Kwan TH.
    Am J Kidney Dis; 2006 Jan 20; 47(1):51-9. PubMed ID: 16377385
    [Abstract] [Full Text] [Related]

  • 9. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R, Dougherty FC, BA 16528 Study Investigators.
    Clin Nephrol; 2007 May 20; 67(5):306-17. PubMed ID: 17542340
    [Abstract] [Full Text] [Related]

  • 10. Achieving chronic kidney disease treatment targets in renal transplant recipients: results from a cross-sectional study in Spain.
    Marcén R, del Castillo D, Capdevila L, Fernandez-Fresnedo G, Rodrigo E, Cantarell C, Fernández-Rodriguez A, López-Oliva MO, Camps J, Aljama P, Ortuño J, Arias M.
    Transplantation; 2009 May 15; 87(9):1340-6. PubMed ID: 19424034
    [Abstract] [Full Text] [Related]

  • 11. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients.
    Voormolen N, Noordzij M, Grootendorst DC, Beetz I, Sijpkens YW, van Manen JG, Boeschoten EW, Huisman RM, Krediet RT, Dekker FW, PREPARE study group.
    Nephrol Dial Transplant; 2007 Oct 15; 22(10):2909-16. PubMed ID: 17517792
    [Abstract] [Full Text] [Related]

  • 12. Factor deficiency in the anemia of renal transplant patients with grade III-IV chronic kidney disease: baseline results of the ARES Study.
    Gentil MA, Pérez-Valdivia MA, López-Mendoza M, Ortega F, Arias M, Gómez-Alamillo C, Campistol JM, ARES Study Group.
    Transplant Proc; 2008 Nov 15; 40(9):2922-4. PubMed ID: 19010148
    [Abstract] [Full Text] [Related]

  • 13. Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease.
    Jones C, Roderick P, Harris S, Rogerson M.
    Nephrol Dial Transplant; 2006 Aug 15; 21(8):2133-43. PubMed ID: 16644779
    [Abstract] [Full Text] [Related]

  • 14. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.
    Perkins RM, Aboudara MC, Uy AL, Olson SW, Cushner HM, Yuan CM.
    Am J Kidney Dis; 2009 Apr 15; 53(4):606-16. PubMed ID: 19216016
    [Abstract] [Full Text] [Related]

  • 15. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration.
    Lawler EV, Gagnon DR, Fink J, Seliger S, Fonda J, Do TP, Gaziano JM, Bradbury BD.
    Nephrol Dial Transplant; 2010 Jul 15; 25(7):2237-44. PubMed ID: 20083469
    [Abstract] [Full Text] [Related]

  • 16. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease.
    Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC.
    Am J Kidney Dis; 2004 Nov 15; 44(5):832-9. PubMed ID: 15492949
    [Abstract] [Full Text] [Related]

  • 17. [Incidence and management of anemia in renal transplantation: an observational-French study].
    Choukroun G, Deray G, Glotz D, Lebranchu Y, Dussol B, Bourbigot B, Lefrançois N, Cassuto-Viguier E, Toupance O, Hacen C, Lang P, Mazouz H, Martinez F.
    Nephrol Ther; 2008 Dec 15; 4(7):575-83. PubMed ID: 18672417
    [Abstract] [Full Text] [Related]

  • 18. Role of erythropoietin in anemia after heart transplantation.
    Gleissner CA, Klingenberg R, Staritz P, Koch A, Ehlermann P, Wiggenhauser A, Dengler TJ.
    Int J Cardiol; 2006 Oct 10; 112(3):341-7. PubMed ID: 16309765
    [Abstract] [Full Text] [Related]

  • 19. Effect of valsartan on erythropoietin and hemoglobin levels in stage III-IV chronic kidney disease patients.
    Durmus A, Dogan E, Erkoc R, Sayarlioglu H, Topal C, Dilek I.
    Int J Clin Pract; 2005 Sep 10; 59(9):1001-4. PubMed ID: 16115171
    [Abstract] [Full Text] [Related]

  • 20. Integrated therapies including erythropoietin decrease the incidence of dialysis: lessons from mapping the incidence of end-stage renal disease in Japan.
    Furumatsu Y, Nagasawa Y, Hamano T, Iwatani H, Iio K, Shoji T, Ito T, Tsubakihara Y, Imai E.
    Nephrol Dial Transplant; 2008 Mar 10; 23(3):984-90. PubMed ID: 17956890
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.